Autoimmune - TYK2 kinase

This programme is a co-development collaboration with SRI International (Menlo Park, CA, USA). We are focused on developing a series of TYK2 inhibitors that can be dosed via the oral route, targeting autoimmune diseases such as:

  • psoriasis;
  • rheumatoid arthritis;
  • inflammatory bowel disease (IBD);
  • lupus;
  • multiple sclerosis.

TYK2 is a member of the Janus kinase (JAK) family of kinases. JAK family kinases are the biochemical targets of several marketed and clinical-stage drugs for cancer and autoimmune diseases. None of these drugs specifically target TYK2, giving us a potentially unique position in this area.

SRI and Sareum are working to complete the lead optimisation phase of discovery, prior to moving into formal preclinical development. In the course of this research we have discovered advanced lead molecules such as SAR-20347, which leads to a striking decrease in symptoms in preclinical disease standard models of psoriasis, rheumatoid arthritis and colitis.

Much of this research was the subject of a presentation at the Federation of Clinical Immunology Societies conference in June 2014 and published in the peer-reviewed Journal of Immunology in October 2014.

Seeking to build on the insights gained from this research, we are synthesising new molecules with improved potency and other properties.

We intend to progress active compounds into other disease models including inflammatory bowel disease, lupus and multiple sclerosis.

Related Items

Sareum/SRI Journal of Immunology paper: Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis.

News Release: Sareum and SRI Announce Co-Development Agreement.



Contact us

Find out more by getting in touch at bd-email.png

  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… via @Sareumplc
    View more